Figure S2


a
TMSB10-L (39.1%)
TMSB10-H (60.9%)
Cases of BC sample
Staining index of TMSB10
b
TCGA (BRCA)
Overall survival
n=523
n=571
TMSB10-L vs TMSB10-H
P = 0.045
HR = 1.39 (1.01 - 1.91)
Cumulative survival (%)
Survival time (months)
c
TCGA (BRCA)
Distant metastasis free survival
n=523
n=571
TMSB10-L vs TMSB10-H
P = 0.002
HR = 2.15 (1.32 - 3.48)
d
Kaplan-Meier Plotter (BC)
Overall survival
n=304
n=813
TMSB10-L vs TMSB10-H
P < 0.001
HR = 1.69 (1.25 - 2.29)
e
Kaplan-Meier Plotter (BC)
Relapse free survival
n=1323
n=2231
TMSB10-L vs TMSB10-H
P < 0.001
HR = 1.62 (1.43 - 1.84)
f
Kaplan-Meier Plotter (BC)
Distant metastasis free survival
n=437
n=1172
TMSB10-L vs TMSB10-H
P = 0.004
HR = 1.44 (1.12 - 1.84)
g
Kaplan-Meier Plotter
(systemically untreated patients of BC)
Relapse free survival
n=287
n=713
TMSB10-L vs TMSB10-H
P < 0.001
HR = 1.56 (1.20 - 2.02)
h
Kaplan-Meier Plotter
(patients with endocrine therapy of BC)
Relapse free survival
n=393
n=456
TMSB10-L vs TMSB10-H
P = 0.022
HR = 1.37 (1.05 - 1.80)
i
Kaplan-Meier Plotter
(patients with chemotherapy of BC)
Relapse free survival
n=183
n=91
TMSB10-L vs TMSB10-H
P = 0.032
HR = 0.64 (0.43 - 0.96)